PPT-Management of Anticoagulants & Antiplatelet Agents Pre

Thomas Savides MD Professor of Clinical Medicine University of California San Diego Disclosures None Learning Objectives Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. AGENTS. COMMUNICATORS. . enabling and engaging the organization. Linda Ld Jacobson, APR. as. Arriving at . Change . management. 2. Explore . today. The 4 + 1 of . change. management. Status of . Tx. : . Real-World Practice. In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx. 1. Patients on chronic OAC with CAD are 7x more likely to receive concomitant antiplatelet tx. Antiplatelet Guidelines. HEART FAILURE. Working Group: . Alan D. Bell, MD, CCFP; James D. . Douketis. , MD, FRCP. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline . recommendations . Fawaz Altuwaijri. ACEM trainee. Introduction. Characteristics . of novel . anticoagulants. Laboratory Testing. Reversal in the bleeding patient. Introduction. Prevalence . atrial fibrillation. . 3.03 million in 2005. Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Management of Anticoagulants & Antiplatelet Agents Pre and Post Endoscopy Thomas Savides, M.D. Professor of Clinical Medicine University of California, San Diego Disclosures None Learning Objectives What are Direct-Acting Oral Anticoagulants DOACsANSWERS by heartTreatments TestscontinuedAdhere to your medication regimen and do not abruptly stop taking your DOACs without 31rst talking with your d September 2017. Promoting Anticoagulation . Safety. An . update on the use of newer . anticoagulants and . antiplatelet therapy. Learning Objectives. Evaluate the proper use of oral anticoagulants and antiplatelet medications (e.g., indications, dosing, monitoring). ?. That . major bleeding . occurs in about . 6.5% of patients on anticoagulants.. . That’s. . 1 patient in 15. . and commonly, GI Bleeding.. That . 1% . is . fatal bleeding . such as intracranial hemorrhage.. Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . intracerebral haemorrhage (ICH): extended follow-up of the. RE. start. or . ST. op. . A. ntithrombotics. . R. andomised . T. rial. (RESTART) . RESTART Collaboration. www.RESTARTtrial.org. Intracerebral haemorrhage (ICH) is associated with an increased risk of arterial ischaemic events*: pooled analysis of 4 population-based cohorts.